Search Results for “aging” – Page 3 – media

GE HealthCare partners with Mayo Clinic to accelerate work on imaging and AI

Dive Brief GE HealthCare has teamed with Mayo Clinic to advance medical imaging, artificial intelligence and theranostics, a type of cancer treatment that involves imaging and targeted therapeutics. The organizations will collaborate on the application of AI to magnetic resonance imaging, the automation of diagnostic and interventional ultrasound and other activities that could improve patient care. GE HealthCare has formed a series of partnerships since separating from its parent company, striking deals with companies including Boston Scientific, Johnson & Johnson and Medtronic. Dive Insight GE HealthCare and other parts of its former parent company, GE, have a long history of working with Rochester, Minnesota-based Mayo, teaming up with the hospital to test remote monitoring devices, found a gene therapy software startup and develop a medical electronic record system. The latest deal brings together scientists, technology developers and clinicians working at GE HealthCare and Mayo to collaborate on four core areas ...
- Source: drugdu
- 125
- September 18, 2023
Multimodal intervention approach shows promise in managing and reversing cognitive impairment

Dr. Heather Sandison, a leading expert in Alzheimer’s Disease and Related Dementia (ADRD) care, has recently published a groundbreaking study in the Journal of Alzheimer’s Disease, highlighting significant improvements in cognitive function among individuals with cognitive decline. The study is the second to employ a multimodal, individualized care plan and offers further hope for managing and potentially reversing cognitive impairment. The study, “Improved Cognition in People with Cognitive Decline: A Multimodal Intervention Approach,” is published in the Journal of Alzheimer’s Disease Volume (94) Issue (3) and focused on individuals with objective cognitive impairment (OCI), a precursor to Alzheimer’s disease. Dr. Sandison and her team recruited 34 participants from the San Diego, CA area to receive a comprehensive intervention based on potential contributors to cognitive decline, such as lifestyle changes, nutraceutical support, and medications. Over the course of six months, the participants underwent regular clinical visits and received ongoing nutrition support ...
- Source: drugdu
- 202
- August 18, 2023
Pfizer Group B Strep Vaccine for Infants Returns Encouraging Mid-Stage Trial Results

Pfizer on Wednesday said its experimental vaccine targeting the potentially deadly bacterial disease Group B Streptococcus returned strong mid-stage clinical trial results, a promising step as the drug inches toward potential approval. Pfizer is among several drugmakers racing to develop the world’s first shot targeting Group B strep disease, which is linked to nearly 150,000 infant deaths worldwide each year, especially in lower-income countries. The Food and Drug Administration in September granted breakthrough therapy designation to Pfizer’s vaccine, which is intended to expedite the development and review of the shot. Pfizer’s single-dose shot generated antibodies that may provide infants with meaningful protection against the disease, according to the data released Wednesday from a phase two clinical trial. The jab is administered to expectant mothers, who pass vaccine-induced antibodies to their fetuses. One of the company’s vaccines targeting respiratory syncytial virus also uses that maternal vaccination method. ...
- Source: drugdu
- 109
- July 21, 2023
‘Aging’ immune cell levels could predict how well we respond to vaccines

Cambridge scientists have identified a signature in the blood that could help predict how well an individual will respond to vaccines. The discovery, published today in Nature Communications, may explain why, even among vulnerable patient groups, some individuals have better responses to vaccines than others. During the COVID-19 pandemic, it has become clear that some patients are better protected by vaccination than others. Many studies have shown that SARS-CoV-2 vaccines are less effective in people with weakened immune systems, but also that this effect is not uniform. Vaccination involves priming the immune system to look for—and get rid of—invading pathogens, such as viruses and bacteria. In part, this involves stimulating the production of antibodies uniquely programmed to identify a particular invader. These antibodies are themselves produced by a type of immune cell known as a B cell. One specific subset of B cells is known as age-associated B cells (ABCs). ...
- Source: drugdu
- 100
- June 29, 2023
Study shows link between death perception and reduced aging in flies

Researchers led by Christi Gendron at the University of Michigan, US, have found the link between death perception and reduced aging in flies. Their new study, published June 13th in the open access journal PLOS Biology shows that a specific group of brain cells in the fly, called R2 and R4 neurons, are activated when flies encounter other dead flies, and that this increased activity leads to more rapid aging. Aging is a complex process that can be affected by both genetics and the environment. While we know that perceptual experiences can affect aging, how this happens is still mostly a mystery. One example is the effect of “death perception” in fruit flies. Previously, the group at the University of Michigan reported that when fruit flies see other dead fruit flies, they experience advanced aging, and that this depends on a type of serotonin receptor. In their new follow-up study, ...
- Source: drugdu
- 123
- June 15, 2023
Indivior’s Opvee crosses FDA finish line, adding new overdose rescue option amid raging opioid epidemic

Just two months after Emergent BioSolutions made history by winning the FDA’s blessing to sell its opioid reversal medicine over the counter, a new treatment option has arrived in Indivior’s Opvee. The nod, which covers Opvee’s use in people 12 years of age and older, marks the first approval for the medicine’s active ingredient in nasal spray form. The molecule, nalmefene hydrochloride, was first approved in the 1990s in an injectable format but was later pulled from the market in 2008. This time around, the FDA endorsed the drug based on new evidence that it can help combat rising overdose rates in the U.S. Indivior, which closed its purchase of Opiant in March and picked up the medicine in that buyout, plans to launch Opvee in the fourth quarter of 2023. The FDA’s approval comes as overdoses attributable to synthetic opioids such as fentanyl are on the rise, with more ...
- Source: drugdu
- 120
- May 25, 2023
Hand-gesture decoding using data from noninvasive brain imaging

Researchers from University of California San Diego have found a way to distinguish among hand gestures that people are making by examining only data from noninvasive brain imaging, without information from the hands themselves. The results are an early step in developing a non-invasive brain-computer interface that may one day allow patients with paralysis, amputated limbs or other physical challenges to use their mind to control a device that assists with everyday tasks. The research, recently published online ahead of print in the journal Cerebral Cortex, represents the best results thus far in distinguishing single-hand gestures using a completely noninvasive technique, in this case, magnetoencephalography (MEG). “Our goal was to bypass invasive components,” said the paper’s senior author Mingxiong Huang, PhD, co-director of the MEG Center at the Qualcomm Institute at UC San Diego. Huang is also affiliated with the Department of Electrical and Computer Engineering at the UC San ...
- Source: drugdu
- 138
- May 22, 2023
Life Bio, Forge to develop gene therapies for aging-linked diseases

Life Biosciences has announced a cGMP manufacturing collaboration with Forge Biologics for advancing the development of new gene therapies to treat aging-related diseases. This partnership aims to help advance the company’s partial epigenetic reprogramming platform for aging-related diseases, such as its lead programme that targets the ophthalmic indications. Through the alliance, Forge Biologics will provide cGMP manufacturing, toxicology, adeno-associated virus (AAV) process development, and analytical services to Life Biosciences. Life Biosciences will use the platform processes of Forge Biologics, including the HEK293 suspension Ignition Cells and per adenovirus helper plasmid. The company stated that all the development and AAV manufacturing works will take place at Forge Biologics’ 200,000ft2 gene therapy facility, called Hearth, located in Columbus, Ohio, US. Life Biosciences CEO Jerry McLaughlin said: “We are delighted to be working with the Forge team, whose expertise in gene therapy manufacturing is unmatched. “We believe we’re on the cusp of revolutionising ...
- Source: drugdu
- 120
- May 11, 2023
Laser speckle imaging can identify hearts suitable for transplantation

In the majority of cases, graft failure after heart transplantation is attributable to abnormalities like severe coronary artery disease. As donors with extended criteria like advanced age and pre-existing heart conditions become eligible for heart transplantation, careful screening for congenital abnormalities has become crucial. Invasive coronary angiography is an essential screening tool that can detect coronary artery disease (CAD), a condition characterized by cholesterol deposits in the heart’s arteries. However, logistical challenges limit utility so it’s used for fewer than a third of donors who are at risk of developing CAD. To overcome this limitation, a new heart preservation procedure called “ex situ heart perfusion” (ESHP) has been developed. By allowing the supply of oxygenated nutrients to the heart via blood vessels, ESHP allows doctors to monitor the performance of the heart and screen it for any defects outside the body. However, coronary angiography conducted during ESHP is known to damage ...
- Source: drugdu
- 215
- April 27, 2023
Scientists develop fastest calcium indicators yet for neural imaging

by Howard Hughes Medical Institute Overview of GCaMP calcium indictors for neuronal imaging. When they sense calcium, GCaMP indicators cause neurons to produce green fluorescent light, allowing scientists to see which neurons and synapses are activated in living animals as they perform a task. Credit: Yan Zhang New ultra-fast sensors developed at Janelia can detect calcium ions nearly as fast as they are released from neurons, allowing scientists to tease out the individual, milliseconds-long signals passing between brain cells. Genetically encoded calcium indicators dubbed GCaMPs are used to track the activity of large populations of neurons in living animals by revealing the calcium ions that are released as signals pass between neurons. When they sense calcium, GCaMP indicators cause the neurons to produce green fluorescent light, allowing scientists to see which neurons and synapses are activated in living animals as they perform a task. GCaMP indicators have become brighter and more sensitive since ...
- Source: drugdu
- 104
- April 6, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.